OGC
REGN icon

Oak Grove Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Oak Grove Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
1,705
-25
-1% -$17K 0.05% 69
2026
Q1 		$1.34M Hold
1,730
– – 0.11% 51
2025
Q4 		$1.34M Sell
1,730
-50
-3% -$34K 0.16% 44
2025
Q3 		$1M Sell
1,780
-800
-31% -$452K 0.14% 42
2025
Q2 		$1.35M Sell
2,580
-450
-15% -$251K 0.22% 41
2025
Q1 		$1.92M Buy
3,030
+100
+3% +$68.8K 0.4% 32
2024
Q4 		$2.09M Buy
2,930
+950
+48% +$797K 0.31% 38
2024
Q3 		$2.08M Buy
1,980
+80
+4% +$89K 0.34% 33
2024
Q2 		$2M Buy
+1,900
New +$1.84M 0.36% 32
2022
Q2 		– Sell
-670
Closed -$468K – 77
2022
Q1 		$468K Sell
670
-300
-31% -$190K 0.09% 61
2021
Q4 		$613K Sell
970
-50
-5% -$30.7K 0.11% 67
2021
Q3 		$617K Buy
1,020
+80
+9% +$49.7K 0.13% 64
2021
Q2 		$525K Buy
940
+220
+31% +$111K 0.12% 70
2021
Q1 		$341K Buy
+720
New +$351K 0.1% 72

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Oak Grove Capital's REGN Position: Q2 2026 in Review

Oak Grove Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q2 2026, selling an estimated $17K and leaving 1,705 shares worth $1.06M. The position accounts for 0.05% of the portfolio, ranked #69.

Oak Grove Capital first reported a position in REGN in Q1 2021 and has held it in 14 quarters since. The position peaked at $2.09M in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Oak Grove Capital held 1,705 shares of Regeneron Pharmaceuticals worth $1.06M as of Q2 2026.
  • Oak Grove Capital sold 25 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $17K.
  • Regeneron Pharmaceuticals made up 0.05% of Oak Grove Capital's portfolio in Q2 2026, its #69 holding.
  • Oak Grove Capital first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Oak Grove Capital's Regeneron Pharmaceuticals position peaked at $2.09M in Q4 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Oak Grove Capital's 13F filing for Q2 2026, filed 13 Aug 2026.